Otolaryngology · 2005 · 46 citations · 15 references
MedicinePharmacologyPharmacotherapyAntimicrobial PharmacologyAntimicrobial PharmacotherapyRhinologyMaxillary Sinus EvaluationOral Bacterial InfectionsAcute Bacterial Sinusitis TreatmentAcute Sinusitis ManagementClinical Trial Efficacy EndpointsLevofloxacin-based TherapyMaxillary Sinus DiseaseMicrosphere DeliveryMicrosphere FormulationsStreptococcus Species
OBJECTIVE: To compare the efficacy and safety of a single 2.0-g dose of a novel azithromycin microsphere formulation with that of 10 days of levofloxacin, 500 mg/d, when used to treat adults with uncomplicated acute bacterial maxillary sinusitis (ABS). STUDY DESIGN AND SETTING: An international, multicenter, randomized, double-blind, double-dummy trial. Eligible outpatients > or =18 years of age with clinical and radiographic evidence of ABS underwent maxillary sinus aspiration before randomization. Primary endpoint was clinical efficacy at the test-of-cure visit (day 17-24). RESULTS: Clinical success rates were 94.5% (242/256) in azithromycin-microspheres-treated patients and 92.8% (233/251) in the levofloxacin group. In patients with documented Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis, clinical cure rates were 97.3% (36/37), 96.3% (26/27), and 100% (8/8), respectively, for the azithromycin group and 92.3% (36/39), 100% (30/30), and 90.9% (10/11), respectively, for the levofloxacin group. CONCLUSIONS: Single-dose azithromycin microspheres provided clinical and bacteriologic efficacy and safety comparable to 10 days of levofloxacin. SIGNIFICANCE: A novel microsphere formulation of azithromycin given as a single dose was safe and effective for the treatment of ABS.
15
Oral Erythromycin and the Risk of Sudden Death from Cardiac Causes
Wayne A. Ray, Katherine T. Murray, Sarah Meredith et al. · New England Journal of Medicine · 2004 · 499 citations · Full text
Medicine, Gynecology, Obstetrics +9
Predicting acute maxillary sinusitis in a general practice population
Jens Hansen, J. Rosborg, E Lund · BMJ · 1995 · 171 citations · Full text
Expanding indications for the new macrolides, azalides, and streptogramins.
Stephen H. Zinner, Lawrence S. Young, J Acar et al. · 1997 · 102 citations